HanAll Biopharma reached its daily trading limit after a surge in buying interest following the announcement of clinical results from its global partner.
According to the Korea Exchange, as of 2:09 PM, HanAll Biopharma's stock rose by the maximum allowable limit of 11,700 won (29.85%) to trade at 50,900 won.
Market analysts noted that Immunovant, HanAll Biopharma's partner, released interim clinical data for its drug candidate, imlifidase (IMVT-1402), for the treatment of refractory rheumatoid arthritis ahead of schedule. The efficacy results exceeded market expectations.
Immunovant previously reported that, in a 16-week interim analysis involving patients with refractory rheumatoid arthritis, the ACR20 response rate was 72.7%, ACR50 was 54.5%, and ACR70 was 35.8%.
ACR measures the improvement in rheumatoid arthritis symptoms, with ACR70 indicating the percentage of patients showing over 70% improvement. This significant symptom improvement in a patient group that had not responded to multiple existing therapies, including first-generation DMARDs, anti-TNF agents, and JAK inhibitors, has drawn attention. Reports also indicated that the treatment demonstrated overall good tolerability without new safety signals.
Imlifidase works by inhibiting FcRn to reduce pathogenic autoantibodies and is currently undergoing global clinical trials for various autoimmune diseases, including myasthenia gravis, CIDP, Sjögren's syndrome, and Graves' disease, in addition to rheumatoid arthritis.
Jung Yi-soo, a researcher at IBK Investment & Securities, stated, "Given that competing FcRn inhibitors have shown poor results in rheumatoid arthritis trials, this positive data could prompt a reevaluation of IMT-1402's potential as a Best-in-Class treatment."
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.